



**Vasomedical, Inc.** provides superior medical products and services that address unmet clinical needs in the management of patients with heart disease.

The company's core technology, EECP® therapy, provides healthcare professionals with a non-invasive therapy for patients suffering from cardiovascular diseases. Recent product diversification from the EECP® therapy systems includes the introduction of BIOX Holter monitoring products. Vasomedical plans to continue to grow the company and introduce other products that provide synergy with our existing product offerings

Over the Counter  
Bulletin Board (OTC BB): VASO.OB

Recent Close (09/21/09): \$0.09

52-week Trading Range: \$0.01– \$0.11

Market Cap. (09/21/09): \$8.49 million

Shares Outstanding: 99.84 million

Loss per Share (MRQ): (\$0.02)

Fiscal Year End: May 31

### EECP® THERAPY: NONINVASIVE THERAPY FOR ISCHEMIC HEART DISEASE

EECP® therapy is a non-invasive, outpatient therapy used in the treatment of ischemic cardiovascular diseases, currently used to manage chronic stable angina and heart failure. The therapy increases blood flow and oxygen supply to the heart muscle and other organs and decreases the heart's workload and need for oxygen, while also improving function of the endothelium, the inner lining of blood vessels throughout the body, lessening resistance to blood flow. These actions reduce or eliminate symptoms of angina and heart failure, and improve the quality of life for thousands of people worldwide.

### EECP® THERAPY: BENEFITS FOR ALL STAKEHOLDERS

Stakeholder	EECP® THERAPY ADVANTAGE
<b>Physicians</b>	Ability to offer a complete treatment regimen for angina and heart failure Incremental source of revenue
<b>Patients</b>	Non-invasive treatment alternative for ischemic heart disease Clinically proven to reduce symptoms, increase activity, improve quality of life
<b>Payers</b>	A more cost effective alternate to costly, high-risk invasive procedures.

CMS established a national Medicare reimbursement policy for EECP® therapy in the treatment of patients with angina and angina-like symptoms in 1999. Extensive third-party coverage policies have been established on an individual provider basis; currently, over 300 third-party payers cover EECP® treatment.

### INVESTMENT CONSIDERATIONS

- **EECP® systems are cleared to market for treating the following four cardiovascular conditions: angina, congestive heart failure, cardiogenic shock and acute myocardial infarction. Currently marketed for angina and heart failure.**
- **Approximately two-thirds of EECP® therapy patients are covered by Medicare.**
- **Approximately three-quarters market share, with over 1,000 EECP® therapy systems installed worldwide.**
- **Opportunity to grow the market for EECP® therapy and further increase sales.**
- **Management and sales team focused on delivering tangible results. Targeted growth strategy with long-term goal of achieving broad-based clinical acceptance of EECP® therapy.**

## MANAGEMENT TEAM

**Jun Ma, Ph.D.**

President and Chief Executive Officer, Director

**John C. K. Hui, Ph.D.**

Senior Vice President,  
Chief Technology Officer, Director

**Tarachand (David) Singh, M.B.A.**

Chief Financial Officer

**Lawrence M. Liebman**

Vice President, Sales and Marketing

## BOARD OF DIRECTORS

**Abraham E. Cohen**

Chairman

**John C. K. Hui, Ph.D.**

Vice Chairman

**Derek Enlander, MD**

**Jun Ma, Ph.D.**

**Behnam Movasheghi, C.P.A.**

**Photios T. Paulson**

**Simon Srybnik**

**Martin Zeiger**

## GROWTH STRATEGY

- Increase penetration of angina and heart failure markets
- Grow the clinical footprint for the application of EEC<sup>®</sup> therapy
- Diversification through introduction of new products and services in non-invasive medicine
- Increase market presence through expanded domestic sales organization and international sales channels
- Demonstrate cost-effectiveness to managed care, capitation, and public health care system

## CORPORATE HEADQUARTERS

**Vasomedical, Inc.**

180 Linden Avenue

Westbury, NY 11590

Phone: (516) 997-4600

Fax: (516) 997-2299

[www.vasomedical.com](http://www.vasomedical.com)

[www.eecp.com](http://www.eecp.com)

[www.naturalbypass.com](http://www.naturalbypass.com)

## INVESTOR RELATIONS

Email: [customerservice@vasomedical.com](mailto:customerservice@vasomedical.com)



This corporate profile may contain forward-looking statements that involve risks and uncertainties. When used herein, words such as "anticipates," "believes," "could," "estimates," "expects," "may," "plans," "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and the information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the risk factors reported from time to time in the Company's SEC reports, including the ability of the Company to continue as a going concern. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.